• MediciNova highlighted March 2026 peer-reviewed research in Cancer Research that supports clinical translation of MN-166 (ibudilast) for brain metastasis.
• Study results were already presented via publication, showing ibudilast blocked an immune-microenvironment pathway tied to brain metastasis progression in preclinical models.
• Findings also point to a potential cerebrospinal fluid biomarker that could guide patient selection in future studies.
• MediciNova plans to work with CNIO researchers on future clinical research in patients with solid tumors that have brain metastases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271900PRIMZONEFULLFEED9707830) on April 27, 2026, and is solely responsible for the information contained therein.